SG11201507274PA - Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis - Google Patents
Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosisInfo
- Publication number
- SG11201507274PA SG11201507274PA SG11201507274PA SG11201507274PA SG11201507274PA SG 11201507274P A SG11201507274P A SG 11201507274PA SG 11201507274P A SG11201507274P A SG 11201507274PA SG 11201507274P A SG11201507274P A SG 11201507274PA SG 11201507274P A SG11201507274P A SG 11201507274PA
- Authority
- SG
- Singapore
- Prior art keywords
- fibrosis
- treatment
- aromatic compounds
- substituted aromatic
- skin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
- C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798427P | 2013-03-15 | 2013-03-15 | |
| PCT/CA2014/000237 WO2014138907A1 (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507274PA true SG11201507274PA (en) | 2015-10-29 |
Family
ID=51535670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507274PA SG11201507274PA (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9884802B2 (enExample) |
| EP (1) | EP2970088B1 (enExample) |
| JP (1) | JP6381557B2 (enExample) |
| KR (1) | KR102303493B1 (enExample) |
| CN (1) | CN105143170B (enExample) |
| AR (1) | AR095427A1 (enExample) |
| AU (1) | AU2014231649C1 (enExample) |
| BR (1) | BR112015023129A2 (enExample) |
| CA (1) | CA2905633C (enExample) |
| CL (1) | CL2015002725A1 (enExample) |
| DK (1) | DK2970088T3 (enExample) |
| EA (1) | EA031511B1 (enExample) |
| ES (1) | ES2780825T3 (enExample) |
| IL (1) | IL241164B (enExample) |
| MX (1) | MX375261B (enExample) |
| MY (1) | MY194727A (enExample) |
| NZ (1) | NZ712745A (enExample) |
| PH (1) | PH12015502012A1 (enExample) |
| PL (1) | PL2970088T3 (enExample) |
| PT (1) | PT2970088T (enExample) |
| SG (1) | SG11201507274PA (enExample) |
| TW (2) | TWI742541B (enExample) |
| UY (1) | UY35401A (enExample) |
| WO (1) | WO2014138907A1 (enExample) |
| ZA (1) | ZA201507062B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| PT3203999T (pt) * | 2014-10-10 | 2020-04-23 | Liminal Biosciences Ltd | Compostos aromáticos substituídos e composições farmacêuticas para a prevenção e tratamento da osteoporose |
| CA2967499C (en) | 2014-11-12 | 2023-01-17 | Prometic Biosciences Inc. | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| WO2016181221A1 (en) | 2015-05-13 | 2016-11-17 | Dignity Sciences Limited | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| US10046007B2 (en) * | 2015-06-24 | 2018-08-14 | Prescient Pharma, Llc | Compositions and methods for treatment of short telomere disorders |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| AU2018367193A1 (en) * | 2017-11-15 | 2020-07-02 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US20210205253A1 (en) * | 2018-05-31 | 2021-07-08 | The Asan Foundation | Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis |
| CN120923343A (zh) | 2018-10-11 | 2025-11-11 | 巴斯夫股份公司 | 芳族化合物及其医药用途 |
| EP3890717A4 (en) * | 2018-12-05 | 2022-08-24 | Liminal Biosciences Limited | USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME |
| WO2020146887A1 (en) | 2019-01-11 | 2020-07-16 | University Of Virginia Patent Foundation | Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis |
| WO2020181163A1 (en) * | 2019-03-06 | 2020-09-10 | Tobira Therapeutics, Inc. | Lipid-based formulation of cenicriviroc |
| WO2021015218A1 (ja) * | 2019-07-24 | 2021-01-28 | 国立大学法人九州大学 | 転写関連因子を標的とする線維化疾患の予防または治療 |
| CN112441916A (zh) * | 2019-08-29 | 2021-03-05 | 广东药科大学 | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 |
| JP2024512510A (ja) * | 2020-10-06 | 2024-03-19 | ファーマセウティーク・インジェニュー・インコーポレイテッド | 置換芳香族化合物及びその医薬組成物 |
| US12053467B2 (en) | 2020-12-18 | 2024-08-06 | NovMeta Pharma Co., Ltd. | Method of treating fibrosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20012434A1 (it) | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| ES2575100T3 (es) * | 2009-05-04 | 2016-06-24 | Prometic Pharma Smt Limited | Compuestos aromáticos sustituidos y usos farmacéuticos de los mismos |
| CA2761061A1 (en) | 2009-05-04 | 2010-11-11 | Prometic Biosciences Inc. | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
| EA030038B1 (ru) * | 2010-10-27 | 2018-06-29 | Прометик Фарма Смт Лимитед | Применение соединений для лечения рака и способ лечения рака |
| CN102070433B (zh) * | 2010-12-27 | 2013-03-27 | 桂林师范高等专科学校 | 芳香基乙酸类衍生物的制备方法 |
| TWI689490B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| CA2967499C (en) * | 2014-11-12 | 2023-01-17 | Prometic Biosciences Inc. | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration |
-
2014
- 2014-03-12 TW TW109106077A patent/TWI742541B/zh not_active IP Right Cessation
- 2014-03-12 TW TW103108714A patent/TWI689489B/zh not_active IP Right Cessation
- 2014-03-13 AR ARP140100971A patent/AR095427A1/es unknown
- 2014-03-13 UY UY0001035401A patent/UY35401A/es not_active Application Discontinuation
- 2014-03-14 JP JP2015561850A patent/JP6381557B2/ja not_active Expired - Fee Related
- 2014-03-14 CA CA2905633A patent/CA2905633C/en active Active
- 2014-03-14 NZ NZ712745A patent/NZ712745A/en not_active IP Right Cessation
- 2014-03-14 MY MYPI2015002292A patent/MY194727A/en unknown
- 2014-03-14 WO PCT/CA2014/000237 patent/WO2014138907A1/en not_active Ceased
- 2014-03-14 MX MX2015012886A patent/MX375261B/es active IP Right Grant
- 2014-03-14 EA EA201591774A patent/EA031511B1/ru not_active IP Right Cessation
- 2014-03-14 DK DK14762607.1T patent/DK2970088T3/da active
- 2014-03-14 AU AU2014231649A patent/AU2014231649C1/en not_active Ceased
- 2014-03-14 EP EP14762607.1A patent/EP2970088B1/en active Active
- 2014-03-14 PL PL14762607T patent/PL2970088T3/pl unknown
- 2014-03-14 SG SG11201507274PA patent/SG11201507274PA/en unknown
- 2014-03-14 ES ES14762607T patent/ES2780825T3/es active Active
- 2014-03-14 US US14/775,882 patent/US9884802B2/en active Active
- 2014-03-14 BR BR112015023129A patent/BR112015023129A2/pt not_active Application Discontinuation
- 2014-03-14 KR KR1020157029285A patent/KR102303493B1/ko not_active Expired - Fee Related
- 2014-03-14 CN CN201480015002.6A patent/CN105143170B/zh not_active Expired - Fee Related
- 2014-03-14 PT PT147626071T patent/PT2970088T/pt unknown
-
2015
- 2015-09-03 IL IL241164A patent/IL241164B/en active IP Right Grant
- 2015-09-09 PH PH12015502012A patent/PH12015502012A1/en unknown
- 2015-09-15 CL CL2015002725A patent/CL2015002725A1/es unknown
- 2015-09-22 ZA ZA2015/07062A patent/ZA201507062B/en unknown
-
2017
- 2017-12-22 US US15/852,977 patent/US10450258B2/en not_active Expired - Fee Related
-
2019
- 2019-09-24 US US16/580,747 patent/US11267779B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201507062B (en) | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | |
| ZA201507061B (en) | Substituted aromatic compounds and related method for the treatment of fibrosis | |
| EP2968323A4 (en) | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | |
| IL258002A (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| EP2968285A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | |
| IL250960A0 (en) | Combined treatment of sinecriviroc for the treatment of leprosy | |
| IL248538B (en) | Vector viruses unrelated to the treatment of lysosomal storage disorders | |
| SG10202102822RA (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | |
| SG11201507459YA (en) | Heterocyclic compounds useful in the treatment of disease | |
| IL246252A0 (en) | Diaminopyrimidyl derivative compounds, their compositions and methods of treatment | |
| PL3027600T3 (pl) | 1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn | |
| ZA201505011B (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| EP3383300A4 (en) | Thermal modification to treat cardiac electrical disorders and other disorders | |
| EP3169259A4 (en) | Cardiac cryolipolysis for the treatment of cardiac arrhythmia | |
| EP2994134A4 (en) | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias | |
| EP3068440A4 (en) | Inhibition of oxidative stress in atrial fibrillation | |
| EP3041514A4 (en) | Reducing the risk of major adverse cardiac events | |
| EP3066077A4 (en) | Treatment of cardiac remodeling and other heart conditions | |
| GB201200688D0 (en) | Aromatic compounds and methods of making the same | |
| EP2953631A4 (en) | Methods of treating heart failure | |
| HUE050456T2 (hu) | Dimetil-amino-mikeliolid tüdõfibrózis kezelésében történõ alkalmazásra | |
| GB201309882D0 (en) | Prevention and treatment of atrial fibrillation | |
| PT3049085T (pt) | Inibidores de sgk1 no tratamento da síndrome do qt longo | |
| GB201404998D0 (en) | Atrial fibrillation therapy | |
| GB201316043D0 (en) | Cardiac arrest treatment |